{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:17:32Z","timestamp":1788268652048,"version":"build-2803163510"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Evaluate the effects of osilodrostat short\u2010 and long\u2010term treatment on health\u2010related quality of life (HRQoL) in Cushing's disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>LINC 3 and LINC 4 studies (pooled analysis).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>185 patients (mean baseline total scores: Cushing's Quality of Life [CushingQoL], 44.0; Beck Depression Inventory II [BDI\u2010II], 15.6; EuroQol Five Dimensions Five Levels [EQ\u2010\u00ad5D\u20105L], 0.7).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements<\/jats:title>\n                    <jats:p>Changes from baseline in CushingQoL, BDI\u2010\u00adII and EQ\u20105D\u20105L scores. CushingQoL and EuroQol Five Dimensions Three Levels (EQ\u20105D\u20103L) scores were assessed in analyses of hypocortisolism\u2010related adverse events (HAEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean CushingQoL score improved (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) by +7.72 (Week [W]12), +11.45 (W26; achieving minimal clinically important difference [MCID]) and +15.32 (W72). Mean BDI\u2010II score improved (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) by \u221219.0% (W12; achieving MCID) and \u221241.2% (W72). EQ\u20105D\u20105L utility score improved over W26\u201372 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), reaching the MCID range at W26. All items\/domains in the HRQoL questionnaires significantly improved over time (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001; ordinal mixed\u2010effects regression), except one BDI\u2010II item (past failure) and one EQ\u20105D\u20105L domain (self\u2010care). CushingQoL total score improved in patients with mild (mean urinary free cortisol [mUFC] \u2264\u20092x upper limit of normal [ULN]), moderate (mUFC\u2009&gt;\u20092\u20135\u2009\u00d7\u2009ULN) and severe (mUFC\u2009&gt;\u20095\u2009\u00d7\u2009ULN) hypercortisolism. BDI\u2010II and EQ\u20105D\u20105L total scores improved in patients with moderate and severe hypercortisolism. Grade 3 HAEs temporarily reduced CushingQoL and EQ\u20105D\u20103L scores during event weeks. In the multivariable models, longer treatment duration was associated with CushingQoL improvements; higher mUFC, higher body mass index, and occurrence of HAEs were associated with lower CushingQoL scores.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Osilodrostat improved HRQoL, with clinically meaningful, consistent improvements across HRQoL assessments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/cen.70166","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:51:03Z","timestamp":1780372263000},"page":"452-463","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Osilodrostat on Health\u2010Related Quality of Life in Cushing's Disease: Analysis of Patient\u2010Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials"],"prefix":"10.1111","volume":"105","author":[{"given":"John","family":"Newell\u2010Price","sequence":"first","affiliation":[{"name":"The School of Medicine and Population Health, University of Sheffield Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly M. K.","family":"Biller","sequence":"additional","affiliation":[{"name":"Neuroendocrine and Pituitary Tumor Clinical Center Massachusetts General Hospital Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[{"name":"Pituitary Center, Departments of Medicine and Neurological Surgery Oregon Health &amp; Science University Portland Oregon USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0832-9926","authenticated-orcid":false,"given":"Beatrice","family":"Gueron","sequence":"additional","affiliation":[{"name":"Recordati Rare Diseases Puteaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Binowski","sequence":"additional","affiliation":[{"name":"MAHTA Intl Sp. z. o. o. Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pa\u0107kowska","sequence":"additional","affiliation":[{"name":"MAHTA Intl Sp. z. o. o. Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f4nica R.","family":"Gadelha","sequence":"additional","affiliation":[{"name":"Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01961-X"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-013-0012-5"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2021.101505"},{"key":"e_1_2_12_5_1","unstructured":"EuroQoL Research Foundation. EQ\u20105D\u20105L. (2025) https:\/\/euroqolorg\/information-and-support\/euroqol-instruments\/eq-5d-5l. Accessed 30 January 2026."},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/occmed\/kqv087"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0692-z"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf103"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-022-01280-6"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30240-0"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0317"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac178"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1236465"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ24-0153"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02359-6"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae201"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291715001270"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.11.015"},{"key":"e_1_2_12_19_1","unstructured":"EuroQoL Research Foundation. EQ\u20105D\u20103L. (2025) accessed January 30 2026 https:\/\/euroqolorg\/information-and-support\/euroqol-instruments\/eq-5d-3l."},{"key":"e_1_2_12_20_1","unstructured":"National Institute for Health and Care Excellence (NICE).Position Statement on Use of the EQ\u20105D\u20105L Value Set for England (updated October 2019).NICE 2019 accessed January 30 2026 https:\/\/www.nice.org.uk\/position-statements\/position-statement-on-use-of-the-eq-5d-5l-value-set-for-england-updated-october-2019."},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12259"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-013-0396-7"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0506"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-020-01103-6"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-022-01263-7"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-012-0452-2"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvaf181"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105743"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-3350"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.662865"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae163.1287"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-024-01450-8"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf206"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharp.2025.03.001"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-1013"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf598"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.70166","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cen.70166","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.70166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:34:48Z","timestamp":1788266088000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cen.70166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/cen.70166"],"URL":"https:\/\/doi.org\/10.1111\/cen.70166","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"2026-02-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}